4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has been given an average rating of “Buy” by the ten analysts that are covering the company, MarketBeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have covered the stock in the last year is $43.63.
A number of analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, August 9th. Chardan Capital restated a “buy” rating and set a $38.00 target price on shares of 4D Molecular Therapeutics in a research report on Wednesday, July 17th. BMO Capital Markets cut their price objective on 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating for the company in a research report on Thursday, July 18th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $40.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, July 22nd.
Read Our Latest Stock Report on 4D Molecular Therapeutics
Insiders Place Their Bets
Institutional Investors Weigh In On 4D Molecular Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of FDMT. Allspring Global Investments Holdings LLC lifted its stake in 4D Molecular Therapeutics by 702.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after acquiring an additional 3,026 shares during the period. Quest Partners LLC boosted its stake in shares of 4D Molecular Therapeutics by 17,409.1% during the second quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock valued at $121,000 after purchasing an additional 5,745 shares in the last quarter. Entropy Technologies LP purchased a new position in 4D Molecular Therapeutics during the first quarter valued at approximately $239,000. Hsbc Holdings PLC purchased a new stake in 4D Molecular Therapeutics during the second quarter worth $246,000. Finally, American Century Companies Inc. bought a new stake in 4D Molecular Therapeutics during the 2nd quarter valued at $268,000. 99.27% of the stock is owned by institutional investors.
4D Molecular Therapeutics Stock Performance
Shares of NASDAQ:FDMT opened at $15.62 on Thursday. 4D Molecular Therapeutics has a 52-week low of $9.44 and a 52-week high of $36.25. The stock has a market capitalization of $807.60 million, a price-to-earnings ratio of -6.40 and a beta of 2.83. The stock’s 50-day simple moving average is $17.78 and its two-hundred day simple moving average is $23.61.
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.09. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $1.90 million. As a group, equities analysts forecast that 4D Molecular Therapeutics will post -2.75 earnings per share for the current fiscal year.
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Featured Articles
- Five stocks we like better than 4D Molecular Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- Why Dick’s Could Be a Slam Dunk for Your Investment Portfolio
- What Are Trending Stocks? Trending Stocks Explained
- Introduction to Fibonacci Retracement Levels
- Investing In Automotive Stocks
- Top 3 Stocks to Outperform the S&P 500 in a Downturn
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.